New Drug Application (NDA)

In Detail

A New Drug Application (NDA) is the comprehensive regulatory submission that a drug sponsor files with the FDA after completing clinical trials, requesting approval to manufacture and market the drug in the United States. The NDA is one of the largest and most complex documents in the regulatory world, often spanning hundreds of thousands of pages. It contains all of the data and analyses from preclinical and clinical testing, including complete results from Phase 1, Phase 2, and Phase 3 trials. The NDA includes detailed sections on the drug's pharmacology, toxicology, clinical efficacy, safety profile, manufacturing process, quality control measures, proposed labeling, and patent information. The FDA assigns a review team of experts — including medical officers, statisticians, chemists, pharmacologists, and microbiologists — who independently evaluate each section of the application. The standard review timeline is 10-12 months from submission, though drugs that address serious conditions may qualify for priority review (6-8 months). During the review, the FDA may issue a Complete Response Letter requesting additional information or studies. The FDA can also convene an advisory committee of outside experts to discuss the application at a public meeting, though the agency is not bound by the committee's recommendation. If approved, the NDA specifies the conditions under which the drug can be marketed, including approved indications, dosing, contraindications, and required warnings. After NDA approval, the sponsor may be required to conduct Phase 4 post-marketing studies to monitor long-term safety.